Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps Sells 5,934 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Erik Phelps sold 5,934 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $67.57, for a total transaction of $400,960.38. Following the completion of the transaction, the executive vice president now directly owns 214,662 shares in the company, valued at $14,504,711.34. This represents a 2.69 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Tempus AI Price Performance

NASDAQ TEM traded up $3.97 during trading hours on Friday, reaching $68.96. The company had a trading volume of 16,292,734 shares, compared to its average volume of 11,766,354. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $79.49. The stock has a 50-day moving average of $44.36 and a 200 day moving average of $48.84. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Wolfe Research began coverage on Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Guggenheim initiated coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Loop Capital dropped their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price target on shares of Tempus AI in a research note on Tuesday, January 14th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $58.55.

Hedge Funds Weigh In On Tempus AI

Large investors have recently made changes to their positions in the stock. ARK Investment Management LLC boosted its holdings in Tempus AI by 132.1% during the 4th quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company’s stock valued at $186,343,000 after acquiring an additional 3,141,487 shares during the period. NEA Management Company LLC lifted its position in shares of Tempus AI by 17.8% during the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after purchasing an additional 813,169 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Tempus AI by 166.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the period. Franklin Resources Inc. grew its holdings in shares of Tempus AI by 1.0% in the third quarter. Franklin Resources Inc. now owns 811,311 shares of the company’s stock valued at $45,920,000 after purchasing an additional 8,387 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in Tempus AI during the 2nd quarter worth approximately $8,067,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.